• darkblurbg

    Developing precision therapies

    for type 1 diabetes

  • darkblurbg

    Intralymphatic immunotherapy

    with Diamyd®


 Dates for financial information and other events
June 2 − June 5, 2021
ATTD 2021
Advanced Technologies & Treatments for Diabetes virtual conference
June 23, 2021
Quarterly Report III
Quarterly Report 3 2020/2021
October 6, 2021
Year-End Report
Year-End Report 2020/2021

Company Presentation

 February 8, 2021

The Phase 3 trial is based on the notion of precision medicine, where only individuals that we know beforehand to have a high likelihood of benefitting from the treatment will be enrolled.

Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 2, 20/21


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research